Pierre Denys, Juan Carlos Castaño Botero, Ricardo Luis Vita Nunes, Barton Wachs, Cristiano Mendes Gomes, Grigory Krivoborodov, Le Mai Tu, Giulio Del-Popolo, Catherine Thompson, Claire Vilain, Magali Volteau, Michael Kennelly
BACKGROUND: Neurogenic detrusor overactivity incontinence (NDOI) is often inadequately managed with oral therapy. OBJECTIVE: To assess efficacy and safety of abobotulinumtoxinA (aboBoNT-A; Dysport®; Ipsen Ltd.) according to etiology of NDOI. DESIGN, SETTING, AND PARTICIPANTS: Two phase III, randomized, double-blind studies (CONTENT1 [NCT02660138] conducted in Asia, Europe and North America; CONTENT2 [NCT02660359] conducted in the Americas, Asia, Europe and Oceania) both included patients with spinal cord injury (SCI) or multiple sclerosis (MS), with inadequately managed NDOI, regularly performing clean intermittent catheterization (CIC)...
January 2023: Neurourology and Urodynamics